Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial: Insight From the Veterans Affairs Healthcare System

被引:18
作者
Jia, Xiaoming [1 ]
Akeroyd, Julia M. [2 ]
Nasir, Khurram [3 ]
Nambi, Vijay [1 ,4 ,5 ]
Ballantyne, Christie M. [1 ,5 ]
Petersen, Laura A. [2 ]
Virani, Salim S. [1 ,2 ,4 ,5 ]
机构
[1] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA
[2] Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev Ctr Innovat, Hlth Policy Qual & Informat Program, Houston, TX USA
[3] Yale Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT USA
[4] Michael E DeBakey VA Med Ctr, Sect Cardiol, Houston, TX USA
[5] Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX USA
关键词
icosapent ethyl;
D O I
10.1161/CIRCULATIONAHA.118.038691
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
引用
收藏
页码:1341 / 1343
页数:3
相关论文
共 5 条
[1]
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia [J].
Bhatt, Deepak L. ;
Steg, P. Gabriel ;
Miller, Michael ;
Brinton, Eliot A. ;
Jacobson, Terry A. ;
Ketchum, Steven B. ;
Doyle, Ralph T., Jr. ;
Juliano, Rebecca A. ;
Jiao, Lixia ;
Granowitz, Craig ;
Tardif, Jean-Claude ;
Ballantyne, Christie M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) :11-22
[2]
IBM Micromedex, 2018, WEB APPL ACC RED BOO
[3]
United States Congressional Budget Office, 2005, PRIC BRAND NAM DRUGS
[4]
US Department of Veterans Affairs: National Acquisition Center (CCST), PHARM CATAL SEARCH
[5]
Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act [J].
Virani, Salim S. ;
Akeroyd, Julia M. ;
Ramsey, David J. ;
Chan, Winston J. ;
Frazier, Lorraine ;
Nasir, Khurram ;
Rajan, Suja S. ;
Ballantyne, Christie M. ;
Petersen, Laura A. .
AMERICAN HEART JOURNAL, 2016, 181 :74-82